CDCA2 upregulation was observed to be associated with shorter overall survival in a subgroup stratified analysis of IDH status (Mut), WHO grade (G3), histological type (astrocytoma and oligodendroglioma), and primary therapy outcome (PD and SD) (S4 Fig). Here, CDCA2 is linked to astrocytoma (excluding glioblastoma).